ASTH Astrana Health, Inc.

“NT 10-K 1 tm267656d2_nt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-37392 CUSIP NUMBER 03763A207 (Check one): Form 10-K o Form 20-F o Form 11-K Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2025 o Transition Report on Form 10-K o Transition Report on Form 20-F o T”

“statements or expectations regarding the material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakness in a timely manner”

“Because this material weakness had not been remediated as of September 30, 2026, management concluded that our disclosure controls and procedures were not effective as of September 30, 2026.”

“As previously disclosed in the Form 10-K for the year ended December 31, 2025, management identified a material weakness in internal control over financial reporting associated with the accounting for business combinations.”

“any statements regarding our ability to remediate the material weakness in our internal control over financial reporting and maintain effective internal control over financial reporting and disclosure controls and procedures”